株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

心房細動:世界薬剤予測および市場分析

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

発行 GlobalData 商品コード 329462
出版日 ページ情報 英文 411 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: GlobalData社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
心房細動:世界薬剤予測および市場分析 PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025
出版日: 2016年08月01日 ページ情報: 英文 411 Pages
概要

当レポートでは、心房細動の概要と治療法、市場収益と予測、パイプライン分析、現在および将来の競合動向、各国別動向、参入企業のプロファイルなどをまとめています。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 病因と病態生理学
  • 症状
  • 心房細動の分類
  • 予後

第4章 疫学

  • 疾患の背景
  • リスクファクターと併存疾患
  • 世界の動向
  • 予測方法
  • 心房細動の疫学的予測
  • ディスカッション

第5章 疾患管理

  • 診断と治療概要
    • 診断
    • 治療ガイドラインと主な処方薬
    • 臨床の現状
  • 米国
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • 日本
  • カナダ

第6章 競合評価

  • 概要
  • 製品プロファイル:抗凝固薬主要ブランド
  • 製品プロファイル:抗不整脈薬主要ブランド
  • その他の治療クラス

第7章 アンメットニーズと機会

  • 概要
  • 洞律動維持のための安全な抗不整脈薬
  • 効果的かつ即時効果のある除細動薬
  • 新経口抗凝固薬の解毒剤
  • 新経口抗凝固薬へのアクセス改善と償還
  • 新経口抗凝固薬の臨床的利点に関する医師への教育充実
  • 新経口抗凝固薬の臨床的利点に関する患者の意識向上

第8章 パイプライン評価

  • 概要
  • 治験マッピング
  • 臨床開発における有望薬剤
  • その他の開発中薬剤

第9章 現在および将来の参入企業

  • 概要
  • 企業戦略動向
  • 企業プロファイル

第10章 市場見通し

  • 世界市場
    • 予測
    • 促進因子と障壁:世界的課題
  • 米国
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • 日本
  • カナダ

第11章 付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC133PIDR

Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregular and often abnormally fast heart rate. Various therapeutic options are available to treat patients with AF, and most patients will receive some form of antithrombotic therapy, a heart rate control agent, and potentially an antiarrhythmic drug for rhythm control.

All sectors of the AF market have historically been saturated with generics, with the vitamin K antagonists such as warfarin playing an important role in stroke prevention in AF. However, since 2010, and the launch of the first of the new oral anticoagulants (NOACs), a shift in the treatment of patients with AF has occurred. The NOACs offer a significant advancement in anticoagulation and their continued uptake will be the main driver of growth in the AF market over the next 10 years.

In contrast, despite a great unmet need for safer antiarrhythmic drugs, developments in this field are expected to be much slower and there are presently no late-stage drug candidates that are expected to address this unmet need during the forecast period.

Highlights

Key Questions Answered

  • The anticoagulant market for stroke prevention in AF has become increasingly crowded. How will the drug treatment landscape for AF change? Which of the NOACs will become the market leader over the next ten years? What are the key drivers and barriers to this change?
  • The AF market is marked by the presence of a number of unmet needs. What are the main unmet needs in the treatment of AF? Will the drugs under development fulfil the unmet needs of the AF market?
  • Will any late-stage anticoagulants drugs make a significant impact on the AF market? What subgroups of the AF population will they target?

Scope

  • Overview of AF, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized AF therapeutics market revenue, annual cost of therapy, and treatment usage pattern data from 2015, forecast for ten years to 2025.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the AF therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global AF therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global AF therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AF therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global AF therapeutics market from 2015-2025.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms
  • 3.3. Classification of Atrial Fibrillation
  • 3.4. Prognosis

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
  • 4.3. Global Trends
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Forecast Assumptions and Methods
    • 4.4.3. Sources Not Used
  • 4.5. Epidemiological Forecast for AF (2015-2025)
    • 4.5.1. Diagnosed Prevalent Cases
  • 4.6. Discussion
    • 4.6.1. Epidemiological Forecast Insight
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis

5. Disease Management

  • 5.1. Diagnosis and Treatment Overview
    • 5.1.1. Diagnosis
    • 5.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 5.1.3. Clinical Practice
  • 5.2. US
  • 5.3. France
  • 5.4. Germany
  • 5.5. Italy
  • 5.6. Spain
  • 5.7. UK
  • 5.8. Japan
  • 5.9. Canada

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Product Profiles - Major Brands, Anticoagulant Agents
    • 6.2.1. Warfarin (Widely Genericized)
    • 6.2.2. Pradaxa (dabigatran)
    • 6.2.3. Xarelto (rivaroxaban)
    • 6.2.4. Eliquis (apixaban)
    • 6.2.5. Savaysa (edoxaban)
  • 6.3. Product Profiles - Major Brands, Antiarrhythmic Drugs
    • 6.3.1. Multaq (dronedarone)
    • 6.3.2. Brinavess (vernakalant)
  • 6.4. Other Therapeutic Classes
    • 6.4.1. Vitamin K Antagonists Other than Warfarin (Widely Genericized)
    • 6.4.2. Antiplatelets - Aspirin (Widely Genericized)
    • 6.4.3. Beta-Blockers - Atenolol, Metoprolol, Propranolol (Widely Genericized)
    • 6.4.4. Calcium Channel Blockers - Diltiazem, Verapamil (Widely Genericized)
    • 6.4.5. Cardiac Glycosides - Digoxin (Widely Genericized)
    • 6.4.6. Potassium Channel Blockers - Amiodarone, Sotalol, Dofetilide (Widely Genericized)
    • 6.4.7. Sodium Channel Blockers - Flecainide, Propafenone (Widely Genericized)

7. Unmet Need and Opportunity

  • 7.1. Overview
  • 7.2. Target Opportunity Profiles in Specific Patient Segments
    • 7.2.1. Atrial Fibrillation Patients with Valvular AF and Mechanical Heart Valves
    • 7.2.2. Atrial Fibrillation Patients with Severe Chronic Kidney Disease or Renal Failure
  • 7.3. Safer Antiarrhythmic Drugs for the Maintenance of Sinus Rhythm
    • 7.3.1. Unmet Need
    • 7.3.2. Gap Analysis
    • 7.3.3. Opportunity
  • 7.4. Effective and Rapid-Acting Cardioversion Drugs
    • 7.4.1. Unmet Need
    • 7.4.2. Gap Analysis
    • 7.4.3. Opportunity
  • 7.5. Therapies for Valvular Atrial Fibrillation Patients
    • 7.5.1. Unmet Need
    • 7.5.2. Gap Analysis
    • 7.5.3. Opportunity
  • 7.6. Therapies for Atrial Fibrillation Patients with Severe Chronic Kidney Disease or Renal Failure
    • 7.6.1. Unmet Need
    • 7.6.2. Gap Analysis
    • 7.6.3. Opportunity
  • 7.7. Improved Access to and Reimbursement of the New Oral Anticoagulants
    • 7.7.1. Unmet Need
    • 7.7.2. Gap Analysis
    • 7.7.3. Opportunity
  • 7.8. Increased Physician Education on the Clinical Benefits of the NOACs
    • 7.8.1. Unmet Need
    • 7.8.2. Gap Analysis
    • 7.8.3. Opportunity
  • 7.9. Increased Patient Awareness of the Clinical Benefits and Proper Use of the NOACs
    • 7.9.1. Unmet Need
    • 7.9.2. Gap Analysis
    • 7.9.3. Opportunity
  • 7.10. Reversal agents for the New Oral Anticoagulants
    • 7.10.1. Unmet Need
    • 7.10.2. Gap Analysis
    • 7.10.3. Opportunity

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Promising Drugs in Clinical Development
    • 8.2.1. Tecarfarin
  • 8.3. Other Drugs in Development
    • 8.3.1. Early-Stage Anticoagulant Pipeline
    • 8.3.2. Early-Stage Antiarrhythmia Pipeline

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles
    • 9.3.1. Boehringer Ingelheim
    • 9.3.2. Bayer
    • 9.3.3. Janssen (Johnson & Johnson)
    • 9.3.4. Bristol-Myers Squibb
    • 9.3.5. Pfizer
    • 9.3.6. Daiichi-Sankyo
    • 9.3.7. Armetheon

10. Market Outlook

  • 10.1. Global Markets
    • 10.1.1. Forecast
    • 10.1.2. Drivers and Barriers - Global Issues
  • 10.2. US
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers
  • 10.3. France
    • 10.3.1. Forecast
    • 10.3.2. Key Events
    • 10.3.3. Drivers and Barriers
  • 10.4. Germany
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers and Barriers
  • 10.5. Italy
    • 10.5.1. Forecast
    • 10.5.2. Key Events
    • 10.5.3. Drivers and Barriers
  • 10.6. Spain
    • 10.6.1. Forecast
    • 10.6.2. Key Events
    • 10.6.3. Drivers and Barriers
  • 10.7. UK
    • 10.7.1. Forecast
    • 10.7.2. Key Events
    • 10.7.3. Drivers and Barriers
  • 10.8. Japan
    • 10.8.1. Forecast
    • 10.8.2. Key Events
    • 10.8.3. Drivers and Barriers
  • 10.9. Canada
    • 10.9.1. Forecast
    • 10.9.2. Key Events
    • 10.9.3. Drivers and Barriers

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Diagnosed Atrial Fibrillation Patients
    • 11.4.2. Percent Drug-Treated Patients
    • 11.4.3. Drugs Included in Each Therapeutic Class
    • 11.4.4. Launch and Patent Expiry Dates
    • 11.4.5. General Pricing Assumptions
    • 11.4.6. Individual Drug Assumptions
    • 11.4.7. Generic Erosion
    • 11.4.8. Pricing of Pipeline Agents
  • 11.5. Physicians and Specialists Included in this Study
  • 11.6. About the Authors
    • 11.6.1. Analyst
    • 11.6.2. Senior Analyst
    • 11.6.3. Therapy Director
    • 11.6.4. Epidemiologist
    • 11.6.5. Global Director of Therapy Analysis and Epidemiology
  • 11.7. About GlobalData
  • 11.8. Disclaimer

List of Tables

  • Table 1: Common Cardiac and Non-cardiac Causes of AF
  • Table 2: Classification of AF
  • Table 3: Clinical Subtypes of AF
  • Table 4: Risk Factors and Comorbidities for AF
  • Table 5: Prevalence (%) of AF as Reported in Epidemiological Studies
  • Table 6: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of AF
  • Table 7: 8MM, Sources Used to Forecast Clinical Subtypes of Diagnosed Prevalent Cases of AF
  • Table 8: 8MM, Sources Not Used in the Epidemiological Analysis of AF
  • Table 9: 8MM, Diagnosed Prevalent Cases of AF, Ages ≥40 Years, Both Sexes, N, Selected Years 2015-2025
  • Table 10: 8MM, Age-Specific Diagnosed Prevalent Cases of AF, Both Sexes, N (Row %), 2015
  • Table 11: 8MM, Sex-Specific Diagnosed Prevalent Cases of AF, Ages ≥40 Years, N (Row %), 2015
  • Table 12: CHADS2 Index for Stroke Risk Assessment
  • Table 13: CHA2DS2-VASc Index for Stroke Risk Assessment
  • Table 14: Treatment Guidelines for AF by Country
  • Table 15: Most Prescribed Drugs or Drug Classes for AF by Country, 2015
  • Table 16: Country Profile - US
  • Table 17: Country Profile - France
  • Table 18: Country Profile - Germany
  • Table 19: Country Profile - Italy
  • Table 20: Country Profile - Spain
  • Table 21: Country Profile - UK
  • Table 22: Country Profile - Japan
  • Table 23: Country Profile - Canada
  • Table 24: Leading Treatments and Branded Drugs for AF, 2016
  • Table 25: Product Profile - Warfarin (Widely Genericized)
  • Table 26: Warfarin (Widely Genericized) SWOT Analysis, 2016
  • Table 27: Global Sales Forecasts ($m) for Warfarin, 2015-2025
  • Table 28: Product Profile - Pradaxa (dabigatran)
  • Table 29: Pradaxa (dabigatran) SWOT Analysis, 2016
  • Table 30: Global Sales Forecasts ($m) for Pradaxa, 2015-2025
  • Table 31: Product Profile - Xarelto (rivaroxaban)
  • Table 32: Xarelto (rivaroxaban) SWOT Analysis, 2016
  • Table 33: Global Sales Forecasts ($m) for Xarelto, 2015-2025
  • Table 34: Product Profile - Eliquis (apixaban)
  • Table 35: Eliquis (apixaban) SWOT Analysis, 2016
  • Table 36: Global Sales Forecasts ($m) for Eliquis, 2015-2025
  • Table 37: Product Profile - Savaysa (edoxaban)
  • Table 38: Savaysa (edoxaban) SWOT Analysis, 2016
  • Table 39: Global Sales Forecasts ($m) for Savaysa, 2015-2025
  • Table 40: Product Profile - Multaq (dronedarone)
  • Table 41: Overview of the Pivotal Clinical Trials for Multaq
  • Table 42: Efficacy of Multaq in Patients with Paroxysmal or Persistent AF/AFL in the ATHENA Study
  • Table 43: Efficacy of Multaq in Patients with Permanent AF in the PALLAS Study
  • Table 44: Multaq (dronedarone) SWOT Analysis, 2016
  • Table 45: Global Sales Forecasts ($m) for Multaq, 2015-2025
  • Table 46: Product Profile - Brinavess (vernakalant)
  • Table 47: Efficacy of Intravenous Brinavess in Pivotal Late-Stage Clinical Trials
  • Table 48: Brinavess (vernakalant) SWOT Analysis, 2016
  • Table 49: Global Sales Forecasts ($m) for Brinavess, 2015-2025
  • Table 50: Summary of Widely Genericized Therapeutic Classes, 2014
  • Table 51: Commonly Used Genericized Vitamin K Antagonists (Excluding Warfarin), by Region
  • Table 52: Unmet Need and Opportunity in AF
  • Table 53: Target Opportunity Profile for AF Patients with Valvular AF and Mechanical Heart Valves
  • Table 54: Target Opportunity Profile for AF Patients with Severe Chronic Kidney Disease or Renal Failure
  • Table 55: Late-Stage Pipeline for AF, 2016
  • Table 56: Therapeutic Classes in Late-Stage Development for AF, 2016
  • Table 57: Product Profile - Tecarfarin
  • Table 58: Treatment-Emergent Adverse Events Reported for >2 Patients in Phase IIa Tecarfarin Study
  • Table 59: Tecarfarin SWOT Analysis, 2016
  • Table 60: Global Sales Forecasts ($m) for Tecarfarin, 2015-2025
  • Table 61: Early-Stage Pipeline Products for AF - Anticoagulant Agents
  • Table 62: Early-Stage Pipeline Products for AF - Antiarrhythmic Drugs
  • Table 63: Key Companies in the AF Market, 2016
  • Table 64: Boehringer Ingelheim's AF Portfolio Assessment, 2016
  • Table 65: Boehringer Ingelheim SWOT Analysis, 2016
  • Table 66: Bayer's AF Portfolio Assessment, 2016
  • Table 67: Bayer SWOT Analysis, 2016
  • Table 68: Janssen's AF Portfolio Assessment, 2016
  • Table 69: Janssen SWOT Analysis, 2016
  • Table 70: Bristol-Myers Squibb's AF Portfolio Assessment, 2016
  • Table 71: Bristol-Myers Squibb SWOT Analysis, 2016
  • Table 72: Pfizer's AF Portfolio Assessment, 2016
  • Table 73: Pfizer SWOT Analysis, 2016
  • Table 74: Daiichi-Sankyo's AF Portfolio Assessment, 2016
  • Table 75: Daiichi-Sankyo SWOT Analysis, 2016
  • Table 76: Armetheon's AF Portfolio Assessment, 2016
  • Table 77: Armetheon SWOT Analysis, 2016
  • Table 78: Global* Sales Forecasts ($m) for AF, 2015-2025
  • Table 79: Global AF Market - Drivers and Barriers, 2016
  • Table 80: Sales Forecasts ($m) for AF in the US, 2015-2025
  • Table 81: Key Events Impacting Sales for AF in the US, 2016
  • Table 82: AF Market - Drivers and Barriers in the US, 2015-2025
  • Table 83: Sales Forecasts ($m) for AF in France, 2015-2025
  • Table 84: Key Events Impacting Sales for AF in France, 2016
  • Table 85: AF Market - Drivers and Barriers in France, 2015-2025
  • Table 86: Sales Forecasts ($m) for AF in Germany, 2015-2025
  • Table 87: Key Events Impacting Sales for AF in Germany, 2016
  • Table 88: AF Market - Drivers and Barriers in Germany, 2015-2025
  • Table 89: Sales Forecasts ($m) for AF in Italy, 2015-2025
  • Table 90: Key Events Impacting Sales for AF in Italy, 2016
  • Table 91: AF Market - Drivers and Barriers in Italy, 2015-2025
  • Table 92: Sales Forecasts ($m) for AF in Spain, 2015-2025
  • Table 93: Key Events Impacting Sales for AF in Spain, 2016
  • Table 94: AF Market - Drivers and Barriers in Spain, 2015-2025
  • Table 95: Sales Forecasts ($m) for AF in the UK, 2015-2025
  • Table 96: Key Events Impacting Sales for AF in the UK, 2016
  • Table 97: AF Market - Drivers and Barriers in the UK, 2015-2025
  • Table 98: Sales Forecasts ($m) for AF in Japan, 2015-2025
  • Table 99: Key Events Impacting Sales for AF in Japan, 2016
  • Table 100: AF Market - Drivers and Barriers in Japan, 2015-2025
  • Table 101: Sales Forecasts ($m) for AF in Canada 2015-2025
  • Table 102: Key Events Impacting Sales for AF in Canada, 2016
  • Table 103: AF Market - Drivers and Barriers in Canada, 2015-2025
  • Table 104: Key Launch Dates
  • Table 105: Key Patent Expiries
  • Table 106: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: 8MM, Diagnosed Prevalent Cases of AF, Ages ≥40 Years, Both Sexes, N, 2015-2025
  • Figure 2: 8MM, Age-Specific Diagnosed Prevalent Cases of AF, Both Sexes, N, 2015
  • Figure 3: 8MM, Sex-Specific Diagnosed Prevalent Cases of AF, Ages ≥40 Years, 2015
  • Figure 4: 8MM, Age-Standardized Diagnosed Prevalence of AF, Ages ≥40 Years, N, 2015
  • Figure 5: 8MM, Diagnosed Prevalent Cases of AF by Clinical Subtypes, Both Sexes, Ages ≥40 Years, 2015
  • Figure 6: ESC Guideline Recommendations for Choosing an Anticoagulant
  • Figure 7: JCS Guideline Recommendations for Choosing an Anticoagulant
  • Figure 8: CCS Guideline Recommendations for Choosing an Anticoagulant
  • Figure 9: AHA Guideline Recommendations for Drug Therapy for Ventricular Rate Control
  • Figure 10: AHA Guideline Recommendations for Rhythm Control in Patients with Paroxysmal and Persistent AF
  • Figure 11: ESC Guideline Recommendations for Rhythm Control According to Underlying Pathology
  • Figure 12: JCS Guideline Recommendations for Rhythm Control
  • Figure 13: Site of Action of the New Oral Anticoagulants in the Anticoagulation Cascade
  • Figure 14: Competitive Assessment of Late-Stage Pipeline Agents for AF, 2015-2025
  • Figure 15: Company Portfolio Gap Analysis in AF, 2015-2025
  • Figure 16: Global Sales for AF by Country, 2015-2025
  • Figure 17: Annual Global Sales for AF by Region, 2015-2025
  • Figure 18: Global* AF Sales by Drug Class, 2015-2025
  • Figure 19: Annual Global* Sales for AF by Drug Class, 2015-2025
  • Figure 20: Annual Global* Sales for the Novel Oral Anticoagulants, 2015-2025
  • Figure 21: Sales for AF in the US by Drug Class, 2015-2025
  • Figure 22: Sales for AF in France by Drug Class, 2015-2025
  • Figure 23: Sales for AF in Germany by Drug Class, 2015-2025
  • Figure 24: Sales for AF in Italy by Drug Class, 2015-2025
  • Figure 25: Sales for AF in Spain by Drug Class, 2015-2025
  • Figure 26: Sales for AF in the UK by Drug Class, 2015-2025
  • Figure 27: Sales for AF in Japan by Drug Class, 2015-2025
  • Figure 28: Sales for AF in Canada by Drug Class, 2015-2025
Back to Top